The DOI matches its Crossref record; 106 of the 106 references it cites were found in a registry or an index.
IDO1 in cancer: a Gemini of immune checkpoints
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Liu, Y., Liang, X., Yin, X., Lv, J., Tang, K., Ma, J., Ji, T., Zhang, H., Dong, W., Jin, X., et al. (2017) · Nature Communications · doi:10.1038/ncomms15207 · Cited by 212
RetractedAdverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Immunogenic cell death and DAMPs in cancer therapy
Krysko, D. V., Garg, A. D., Kaczmarek, A., Krysko, O., Agostinis, P., & Vandenabeele, P. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3380 · Cited by 3,223
Prevention of Allogeneic Fetal Rejection by Tryptophan Catabolism
Munn, D. H., Zhou, M., Attwood, J. T., Bondarev, I., Conway, S. J., Marshall, B., Brown, C., & Mellor, A. L. (1998) · Science · doi:10.1126/science.281.5380.1191 · Cited by 2,585
Ido expression by dendritic cells: tolerance and tryptophan catabolism
Mellor, A. L., & Munn, D. H. (2004) · Nature Reviews Immunology · doi:10.1038/nri1457 · Cited by 2,341
Uyttenhove, C., Pilotte, L., Théate, I., Stroobant, V., Colau, D., Parmentier, N., Boon, T., & Van den Eynde, B. J. (2003) · Nature Medicine · doi:10.1038/nm934 · Cited by 2,305
An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor
Opitz, C. A., Litzenburger, U. M., Sahm, F., Ott, M., Tritschler, I., Trump, S., Schumacher, T., Jestaedt, L., Schrenk, D., Weller, M., et al. (2011) · Nature · doi:10.1038/nature10491 · Cited by 1,898
Inhibition of T Cell Proliferation by Macrophage Tryptophan Catabolism
Munn, D. H., Shafizadeh, E., Attwood, J. T., Bondarev, I., Pashine, A., & Mellor, A. L. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.9.1363 · Cited by 1,623
Corrales, L., Glickman, L. H., McWhirter, S. M., Kanne, D. B., Sivick, K. E., Katibah, G. E., Woo, S.-R., Lemmens, E., Banda, T., Leong, J. J., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.04.031 · Cited by 1,560
Rizvi, N. A., Mazières, J., Planchard, D., Stinchcombe, T. E., Dy, G. K., Antonia, S. J., Horn, L., Lena, H., Minenza, E., Mennecier, B., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70054-9 · Cited by 1,415
Modulation of tryptophan catabolism by regulatory T cells
Fallarino, F., Grohmann, U., Hwang, K. W., Orabona, C., Vacca, C., Bianchi, R., Belladonna, M. L., Fioretti, M. C., Alegre, M.-L., & Puccetti, P. (2003) · Nature Immunology · doi:10.1038/ni1003 · Cited by 1,374
Indoleamine 2,3-dioxygenase and tumor-induced tolerance
Munn, D. H., & Mellor, A. L. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31178 · Cited by 1,078
Relationship between interferon‐γ, indoleamine 2,3‐dioxygenase, and tryptophan catabolism
Taylor, M. W., & Feng, G. (1991) · The FASEB Journal · doi:10.1096/fasebj.5.11.1907934 · Cited by 1,060
IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance
Munn, D. H., & Mellor, A. L. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.01.002 · Cited by 1,041
Glucose Metabolism Regulates T Cell Activation, Differentiation, and Functions
Palmer, C. S., Ostrowski, M., Balderson, B., Christian, N., & Crowe, S. M. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00001 · Cited by 988
Combination cancer immunotherapies tailored to the tumour microenvironment
Smyth, M. J., Ngiow, S. F., Ribas, A., & Teng, M. W. L. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.209 · Cited by 944
The future of cancer treatment: immunomodulation, CARs and combination immunotherapy
Khalil, D. N., Smith, E. L., Brentjens, R. J., & Wolchok, J. D. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.25 · Cited by 929
Endogenous kynurenines as targets for drug discovery and development
Stone, T. W., & Darlington, L. G. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd870 · Cited by 768
Tolerance, DCs and tryptophan: much ado about IDO
Grohmann, U. (2003) · Trends in Immunology · doi:10.1016/s1471-4906(03)00072-3 · Cited by 766
Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells
Pallotta, M. T., Orabona, C., Volpi, C., Vacca, C., Belladonna, M. L., Bianchi, R., Servillo, G., Brunacci, C., Calvitti, M., Bicciato, S., et al. (2011) · Nature Immunology · doi:10.1038/ni.2077 · Cited by 703
L-Tryptophan: Basic Metabolic Functions, Behavioral Research and Therapeutic Indications
Richard, D. M., Dawes, M. A., Mathias, C. W., Acheson, A., Hill-Kapturczak, N., & Dougherty, D. M. (2009) · International Journal of Tryptophan Research · doi:10.4137/ijtr.s2129 · Cited by 693
Holmgaard, R. B., Zamarin, D., Munn, D. H., Wolchok, J. D., & Allison, J. P. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130066 · Cited by 634
Brandacher, G., Perathoner, A., Ladurner, R., Schneeberger, S., Obrist, P., Winkler, C., Werner, E. R., Werner-Felmayer, G., Weiss, H. G., G√∂bel, G., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1966 · Cited by 614
Yu, J., Du, W., Yan, F., Wang, Y., Li, H., Cao, S., Yu, W., Shen, C., Liu, J., & Ren, X. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1201449 · Cited by 606
Hou, D.-Y., Muller, A. J., Sharma, M. D., DuHadaway, J., Banerjee, T., Johnson, M., Mellor, A. L., Prendergast, G. C., & Munn, D. H. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2925 · Cited by 586
Wainwright, D. A., Chang, A. L., Dey, M., Balyasnikova, I. V., Kim, C. K., Tobias, A., Cheng, Y., Kim, J. W., Qiao, J., Zhang, L., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0514 · Cited by 576
Self-citationSpranger, S., Koblish, H. K., Horton, B., Scherle, P. A., Newton, R., & Gajewski, T. F. (2014) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-2-3 · Cited by 552
Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity
Liu, X., Shin, N., Koblish, H. K., Yang, G., Wang, Q., Wang, K., Leffet, L., Hansbury, M. J., Thomas, B., Rupar, M., et al. (2010) · Blood · doi:10.1182/blood-2009-09-246124 · Cited by 548
Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner
Holmgaard, R. B., Zamarin, D., Li, Y., Gasmi, B., Munn, D. H., Allison, J. P., Merghoub, T., & Wolchok, J. D. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.08.077 · Cited by 482
Wainwright, D. A., Balyasnikova, I. V., Chang, A. L., Ahmed, A. U., Moon, K.-S., Auffinger, B., Tobias, A. L., Han, Y., & Lesniak, M. S. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2130 · Cited by 472
Self-citationTreatment of Autoimmune Neuroinflammation with a Synthetic Tryptophan Metabolite
Platten, M., Ho, P. P., Youssef, S., Fontoura, P., Garren, H., Hur, E. M., Gupta, R., Lee, L. Y., Kidd, B. A., Robinson, W. H., et al. (2005) · Science · doi:10.1126/science.1117634 · Cited by 425
Mellor, A. L., Sivakumar, J., Chandler, P., Smith, K., Molina, H., Mao, D., & Munn, D. H. (2001) · Nature Immunology · doi:10.1038/83183 · Cited by 423
A two-step induction of indoleamine 2,3 dioxygenase (IDO) activity during dendritic-cell maturation
Braun, D., Longman, R. S., & Albert, M. L. (2005) · Blood · doi:10.1182/blood-2005-03-0979 · Cited by 391
Okamoto, A., Nikaido, T., Ochiai, K., Takakura, S., Saito, M., Aoki, Y., Ishii, N., Yanaihara, N., Yamada, K., Takikawa, O., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2671 · Cited by 390
Indoleamine 2,3‐dioxygenase contributes to tumor cell evasion of T cell‐mediated rejection
Friberg, M., Jennings, R., Alsarraj, M., Dessureault, S., Cantor, A., Extermann, M., Mellor, A. L., Munn, D. H., & Antonia, S. J. (2002) · International Journal of Cancer · doi:10.1002/ijc.10645 · Cited by 365
Théate, I., van Baren, N., Pilotte, L., Moulin, P., Larrieu, P., Renauld, J.-C., Hervé, C., Gutierrez-Roelens, I., Marbaix, E., Sempoux, C., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0137 · Cited by 363
Aire-Dependent Thymic Development of Tumor-Associated Regulatory T Cells
Malchow, S., Leventhal, D. S., Nishi, S., Fischer, B. I., Shen, L., Paner, G. P., Amit, A. S., Kang, C., Geddes, J. E., Allison, J. P., et al. (2013) · Science · doi:10.1126/science.1233913 · Cited by 328
Trial watch: IDO inhibitors in cancer therapy
Vacchelli, E., Aranda, F., Eggermont, A., Sautès-Fridman, C., Tartour, E., Kennedy, E. P., Platten, M., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2014) · OncoImmunology · doi:10.4161/21624011.2014.957994 · Cited by 326
STING Promotes the Growth of Tumors Characterized by Low Antigenicity via IDO Activation
Lemos, H., Mohamed, E., Huang, L., Ou, R., Pacholczyk, G., Arbab, A. S., Munn, D., & Mellor, A. L. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1456 · Cited by 325
Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy
Zhai, L., Spranger, S., Binder, D. C., Gritsina, G., Lauing, K. L., Giles, F. J., & Wainwright, D. A. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0420 · Cited by 322
Self-citationBeatty, G. L., O'Dwyer, P. J., Clark, J., Shi, J. G., Bowman, K. J., Scherle, P. A., Newton, R. C., Schaub, R., Maleski, J., Leopold, L., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2272 · Cited by 314
Löb, S., Königsrainer, A., Zieker, D., Brücher, B. L. D. M., Rammensee, H.-G., Opelz, G., & Terness, P. (2009) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-008-0513-6 · Cited by 304
Aryl hydrocarbon receptor signaling mediates expression of indoleamine 2,3-dioxygenase
Vogel, C. F. A., Goth, S. R., Dong, B., Pessah, I. N., & Matsumura, F. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.07.156 · Cited by 296
Mellor, A. L., Baban, B., Chandler, P. R., Manlapat, A., Kahler, D. J., & Munn, D. H. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.9.5601 · Cited by 290
Increased serum kynurenine/tryptophan ratio correlates with disease progression in lung cancer
Suzuki, Y., Suda, T., Furuhashi, K., Suzuki, M., Fujie, M., Hahimoto, D., Nakamura, Y., Inui, N., Nakamura, H., & Chida, K. (2010) · Lung Cancer · doi:10.1016/j.lungcan.2009.05.001 · Cited by 261
Jitschin, R., Braun, M., Büttner, M., Dettmer-Wilde, K., Bricks, J., Berger, J., Eckart, M. J., Krause, S. W., Oefner, P. J., Le Blanc, K., et al. (2014) · Blood · doi:10.1182/blood-2013-12-546416 · Cited by 251
Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer
Ino, K., Yoshida, N., Kajiyama, H., Shibata, K., Yamamoto, E., Kidokoro, K., Takahashi, N., Terauchi, M., Nawa, A., Nomura, S., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603477 · Cited by 248
Koblish, H. K., Hansbury, M. J., Bowman, K. J., Yang, G., Neilan, C. L., Haley, P. J., Burn, T. C., Waeltz, P., Sparks, R. B., Yue, E. W., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0628 · Cited by 242
Tryptophan-Degrading Enzymes in Tumoral Immune Resistance
van Baren, N., & Van den Eynde, B. J. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00034 · Cited by 228
Fujigaki, S., Saito, K., Sekikawa, K., Tone, S., Takikawa, O., Fujii, H., Wada, H., Noma, A., & Seishima, M. (2001) · European Journal of Immunology · doi:10.1002/1521-4141(200108)31:8<2313::aid-immu2313>3.0.co;2-s · Cited by 213
Challenges in the Discovery of Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors
Röhrig, U. F., Majjigapu, S. R., Vogel, P., Zoete, V., & Michielin, O. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00326 · Cited by 204
Tolerance to apoptotic cells is regulated by indoleamine 2,3-dioxygenase
Ravishankar, B., Liu, H., Shinde, R., Chandler, P., Baban, B., Tanaka, M., Munn, D. H., Mellor, A. L., Karlsson, M. C. I., & McGaha, T. L. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1117736109 · Cited by 198
Kynurenine as an Intermediate in the Formation of Nicotinic Acid from Tryptophane by Neurospora
Beadle, G. W., Mitchell, H. K., & Nyc, J. F. (1947) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.33.6.155 · Cited by 182
Yoshida, R., & Hayaishi, O. (1978) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.75.8.3998 · Cited by 181
Hayashi, T., Mo, J.-H., Gong, X., Rossetto, C., Jang, A., Beck, L., Elliott, G. I., Kufareva, I., Abagyan, R., Broide, D. H., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709261104 · Cited by 179
Babcock, T. A., & Carlin, J. M. (2000) · Cytokine · doi:10.1006/cyto.1999.0661 · Cited by 178
Zhai, L., Ladomersky, E., Lauing, K. L., Wu, M., Genet, M., Gritsina, G., Győrffy, B., Brastianos, P. K., Binder, D. C., Sosman, J. A., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0120 · Cited by 177
Self-citationThe Aryl Hydrocarbon Receptor Preferentially Marks and Promotes Gut Regulatory T Cells
Ye, J., Qiu, J., Bostick, J. W., Ueda, A., Schjerven, H., Li, S., Jobin, C., Chen, Z.-M. E., & Zhou, L. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.10.114 · Cited by 175
Soliman, H. H., Jackson, E., Neuger, T., Dees, E. C., Harvey, R. D., Han, H., Ismail-Khan, R., Minton, S., Vahanian, N. N., Link, C., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2357 · Cited by 174
The PTEN pathway in T regs is a critical driver of the suppressive tumor microenvironment
Sharma, M. D., Shinde, R., McGaha, T. L., Huang, L., Holmgaard, R. B., Wolchok, J. D., Mautino, M. R., Celis, E., Sharpe, A. H., Francisco, L. M., et al. (2015) · Science Advances · doi:10.1126/sciadv.1500845 · Cited by 171
Riesenberg, R., Weiler, C., Spring, O., Eder, M., Buchner, A., Popp, T., Castro, M., Kammerer, R., Takikawa, O., Hatz, R. A., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0942 · Cited by 170
Expression and prognosis role of indoleamine 2,3-dioxygenase in hepatocellular carcinoma
Pan, K., Wang, H., Chen, M.-S., Zhang, H.-K., Weng, D.-S., Zhou, J., Huang, W., Li, J.-J., Song, H.-F., & Xia, J.-C. (2008) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-008-0395-1 · Cited by 169
Piras, F., Colombari, R., Minerba, L., Murtas, D., Floris, C., Maxia, C., Corbu, A., Perra, M. T., & Sirigu, P. (2005) · Cancer · doi:10.1002/cncr.21283 · Cited by 168
Levo- but not dextro-1-methyl tryptophan abrogates the IDO activity of human dendritic cells
Lob, S., Konigsrainer, A., Schafer, R., Rammensee, H.-G., Opelz, G., & Terness, P. (2008) · Blood · doi:10.1182/blood-2007-10-116111 · Cited by 167
Astigiano, S., Morandi, B., Costa, R., Mastracci, L., D'Agostino, A., Ratto, G. B., Melioli, G., & Frumento, G. (2005) · Neoplasia · doi:10.1593/neo.04658 · Cited by 163
Fibrocytes represent a novel MDSC subset circulating in patients with metastatic cancer
Zhang, H., Maric, I., DiPrima, M. J., Khan, J., Orentas, R. J., Kaplan, R. N., & Mackall, C. L. (2013) · Blood · doi:10.1182/blood-2012-08-449413 · Cited by 163
Ravishankar, B., Liu, H., Shinde, R., Chaudhary, K., Xiao, W., Bradley, J., Koritzinsky, M., Madaio, M. P., & McGaha, T. L. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1504276112 · Cited by 162
Shrimali, R. K., Ahmad, S., Verma, V., Zeng, P., Ananth, S., Gaur, P., Gittelman, R. M., Yusko, E., Sanders, C., Robins, H., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0292 · Cited by 161
Opitz, C. A., Litzenburger, U. M., Opitz, U., Sahm, F., Ochs, K., Lutz, C., Wick, W., & Platten, M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019823 · Cited by 159
Li, M., Bolduc, A. R., Hoda, M. N., Gamble, D. N., Dolisca, S.-B., Bolduc, A., Hoang, K., Ashley, C., McCall, D. C., Rojiani, A. M., et al. (2014) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-2-21 · Cited by 151
A phase I study of indoximod in patients with advanced malignancies
Soliman, H. H., Minton, S. E., Han, H. S., Ismail-Khan, R. R., Neuger, A. M., Khambati, F. A., Noyes, D. R., Lush, R. M., Chiappori, A., Roberts, J. D., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8216 · Cited by 149
Knox, W. E. (1951) · PubMed · Cited by 148
Human Tryptophan Dioxygenase: A Comparison to Indoleamine 2,3-Dioxygenase
Batabyal, D., & Yeh, S. (2007) · Journal of the American Chemical Society · doi:10.1021/ja076186k · Cited by 147
Blocking IDO activity to enhance anti-tumor immunity
Munn, D. H. (2012) · Frontiers in Bioscience-Elite · doi:10.2741/e414 · Cited by 146
Targeting Tregs in Malignant Brain Cancer: Overcoming IDO
Wainwright, D. A., Dey, M., Chang, A. L., & Lesniak, M. S. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00116 · Cited by 144
Self-citationIDO2 in Immunomodulation and Autoimmune Disease
Prendergast, G. C., Metz, R. A., Muller, A. J., Merlo, L. M. F., & Mandik‐Nayak, L. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00585 · Cited by 140
Hassanain, H. H., Chon, S. Y., & Gupta, S. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)53504-3 · Cited by 139
Functional and phenotypic effects of AhR activation in inflammatory dendritic cells
Bankoti, J., Rase, B., Simones, T., & Shepherd, D. M. (2010) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2010.03.013 · Cited by 136
Thymus-derived rather than tumor-induced regulatory T cells predominate in brain tumors
Wainwright, D. A., Sengupta, S., Han, Y., & Lesniak, M. S. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor134 · Cited by 134
Self-citationIversen, T. Z., Engell-Noerregaard, L., Ellebæk, E., Andersen, R. S., Larsen, S. K., Bjoern, J., Zeyher, C., Gouttefangeas, C., Thomsen, B. M., Holm, B., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1560 · Cited by 129
Huang, L., Li, L., Lemos, H. D. P., Chandler, P., Pacholczyk, G. A., Baban, B., Barber, G. N., Hayakawa, Y., McGaha, T. L., Ravishankar, B., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1301419 · Cited by 128
Pantouris, G., Serys, M., Yuasa, H. J., Ball, H. J., & Mowat, C. G. (2014) · Amino Acids · doi:10.1007/s00726-014-1766-3 · Cited by 127
Ravishankar, B., Shinde, R. S., Liu, H., Chaudhary, K., Bradley, J., Lemos, H. D. P., Chandler, P., Tanaka, M., Munn, D. H., Mellor, A. L., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1320924111 · Cited by 116
Blocking IDO activity to enhance anti-tumor immunity
David, H. M. (2011) · Frontiers in Bioscience-Elite · doi:10.2741/414 · Cited by 116
Chamuleau, M. E. D., van de Loosdrecht, A. A., Hess, C. J., Janssen, J. J. W. M., Zevenbergen, A., Delwel, R., Valk, P. J. M., Löwenberg, B., & Ossenkoppele, G. J. (2008) · Haematologica · doi:10.3324/haematol.13113 · Cited by 115
Takao, M., Okamoto, A., Nikaido, T., Urashima, M., Takakura, S., Saito, M., Saito, M., Okamoto, S., Takikawa, O., Sasaki, H., et al. (2007) · Oncology Reports · doi:10.3892/or.17.6.1333 · Cited by 97
Perez, R. P., Riese, M. J., Lewis, K. D., Saleh, M. N., DAUD, A. I., Berlin, J. D., Lee, J. J., Mukhopadhyay, S., Zhou, L., Serbest, G., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.3003 · Cited by 95
Immunoactivative role of indoleamine 2,3‐dioxygenase in human hepatocellular carcinoma
Ishio, T., Goto, S., Tahara, K., Toné, S., Kawano, K., & Kitano, S. (2004) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2003.03259.x · Cited by 91
Siu, L. L., Gelmon, K. A., Chu, Q. S.-C., Pachynski, R. K., Alese, O. B., Basciano, P. A., Walker, J., Mitra, P., Zhu, L., Phillips, P., et al. (2017) · Cancer Research · doi:10.1158/1538-7445.am2017-ct116 · Cited by 88
Chamuleau, M. E. D., van de Loosdrecht, A. A., Hess, C. J., Janssen, J. J. W. M., Zevenbergen, A., Delwel, R., Valk, P. J. M., Löwenberg, B., & Ossenkoppele, G. J. (2008) · Haematologica · doi:10.3324/haematol.13112 · Cited by 86
Gangadhar, T. C., Hamid, O., Smith, D. C., Bauer, T. M., Wasser, J. S., Luke, J. J., Balmanoukian, A. S., Kaufman, D. R., Zhao, Y., Maleski, J. E., et al. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-3-s2-o7 · Cited by 77
Characterization and evolution of vertebrate indoleamine 2, 3-dioxygenases
Yuasa, H. J., Ball, H. J., Ho, Y. F., Austin, C., Whittington, C. M., Belov, K., Maghzal, G. J., Jermiin, L. S., & Hunt, N. H. (2009) · Comparative Biochemistry and Physiology Part B Biochemistry and Molecular Biology · doi:10.1016/j.cbpb.2009.02.002 · Cited by 72
High expression of indoleamine 2,3-dioxygenase gene in prostate cancer
Feder‐Mengus, C., Wyler, S. F., Hudolin, T., Ruszat, R., Bubendorf, L., Chiarugi, A., Pittelli, M. G., Weber, W. P., Bachmann, A., Gasser, T. C., et al. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.05.023 · Cited by 72
A high-affinity, tryptophan-selective amino acid transport system in human macrophages
Seymour, R. L., Ganapathy, V., Mellor, A. L., & Munn, D. H. (2006) · Journal of Leukocyte Biology · doi:10.1189/jlb.1205727 · Cited by 69
Ott, M., Litzenburger, U. M., Rauschenbach, K. J., Bunse, L., Ochs, K., Sahm, F., Pusch, S., Opitz, C. A., Blaes, J., von Deimling, A., et al. (2014) · Glia · doi:10.1002/glia.22734 · Cited by 59
Zhai, L., Ladomersky, E., Dostal, C. R., Lauing, K. L., Swoap, K., Billingham, L. K., Gritsina, G., Wu, M., McCusker, R. H., Binder, D. C., et al. (2017) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2017.01.022 · Cited by 55
Self-citationThe Human Indoleamine 2,3-Dioxygenase Gene and Related Human Genes
Murray, M. F. (2007) · Current Drug Metabolism · doi:10.2174/138920007780362509 · Cited by 46
Xin, Y., & Cai, H. (2016) · Molecular Imaging and Biology · doi:10.1007/s11307-016-1024-z · Cited by 44
Spira, A. I., Hamid, O., Bauer, T. M., Borges, V. F., Wasser, J. S., Smith, D. C., Clark, A. S., Schmidt, E. V., Zhao, Y., Maleski, J. E., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.1103 · Cited by 43
Solito, S., Pinton, L., Damuzzo, V., & Mandruzzato, S. (2012) · Immunological Investigations · doi:10.3109/08820139.2012.678023 · Cited by 40
Tang, T., Gill, H. S., Ogasawara, A. K., Tinianow, J. N., Vanderbilt, A. N., Williams, S., Hatzivassiliou, G., White, S. L. P., Sandoval, W. N., DeMent, K., et al. (2017) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2017.05.001 · Cited by 23
[Study of indoleamine 2,3-dioxygenase expression in patients of esophageal squamous cell carcinoma].
Sakurai, K., Enomoto, K., Amano, S., et al. (2004) · PubMed · Cited by 19
Mautino, M. R., Metz, R. A., Jaipuri, F. A., Waldo, J. P., Kumar, S., Marcinowicz-Flick, A., Potturi, H., Adams, J. T., Allen, C. V., Vahanian, N. N., et al. (2014) · Cancer Research · doi:10.1158/1538-7445.am2014-1633 · Cited by 5
Cited by
Klemm, F., Maas, R. R., Bowman, R. L., Kornete, M., Soukup, K., Nassiri, S., Brouland, J.-P., Iacobuzio-Donahue, C. A., Brennan, C., Tabar, V., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.007 · Cited by 1,037
Tryptophan metabolism in health and disease
Xue, C., Li, G., Zheng, Q., Gu, X., Shi, Q., Su, Y., Chu, Q., Yuan, X., Bao, Z., Lu, J., et al. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.06.004 · Cited by 961
Glioma targeted therapy: insight into future of molecular approaches
Yang, K., Wu, Z., Zhang, H., Zhang, N., Wu, W., Wang, Z., Dai, Z., Zhang, X., Zhang, L., Peng, Y., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01513-z · Cited by 704
Interferon-γ: teammate or opponent in the tumour microenvironment?
Gocher, A. M., Workman, C. J., & Vignali, D. A. A. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00566-3 · Cited by 582
Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer
Zhang, H., Dai, Z., Wu, W., Wang, Z., Zhang, N., Zhang, L., Zeng, W.-J., Liu, Z., & Cheng, Q. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01987-7 · Cited by 535
Metadata
- Authors
- Zhai, L., Ladomersky, E., Lenzen, A., Nguyen, B., Patel, R., Lauing, K. L., Wu, M., & Wainwright, D. A.
- Venue
- Cellular & Molecular Immunology
- Published
- 2018-01-29
- Volume
- 15
- Issue
- 5
- Pages
- 447-457
- ISSN
- 1672-7681 (ISSN-L)
- 2042-0226
- OpenAlex
- W2786095824
- Cited by
- 437
- References
- 106
- FWCI
- 12.72
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.